The pharmaceutical world is observing a remarkable shift in diabetes therapy with the introduction of GLP-1 transdermal devices. These devices offer a possibly more comfortable alternative to shots of GLP-1 receptor agonists, minimizing the need for daily needle pokes. The innovation delivers the compound directly through the surface, arguably e… Read More